Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.

@article{Mullins2017ExtendedHP,
  title={Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.},
  author={Eric S Mullins and Oleksandra Stasyshyn and Mar{\'i}a Teresa {\'A}lvarez-Rom{\'a}n and David Osman and Ri J Liesner and Werner Engl and Marlies Sharkhawy and Brigitt E Abbuehl},
  journal={Haemophilia : the official journal of the World Federation of Hemophilia},
  year={2017},
  volume={23 2},
  pages={238-246}
}
INTRODUCTION Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T1/2 ) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. AIMS To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

Extended Half-Life Factor VIII and Factor IX Preparations.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie • 2018

References

Publications referenced by this paper.
Showing 1-10 of 30 references

A multicenter study of recombinant factor VIII ( Recombinate ) in previously treated patients with hemophilia A

White GC, S Courter, GL Bray, M Lee, ED Gomperts
Thromb Haemost • 2012

Similar Papers

Loading similar papers…